Laryngeal Extracellular Matrix Biomarkers in Voice Health

Abstract

The extracellular matrix (ECM) of the larynx plays a critical role in vocal fold structure, function, and overall voice health. Recent advances in biomarker discovery have elucidated specific ECM components and their alterations in laryngeal pathology, offering new avenues for diagnosis, prognosis, and therapeutic strategies. This review synthesizes current evidence on ECM biomarkers in the context of voice disorders, with an emphasis on their clinical relevance, mechanistic underpinnings, and potential integration into routine otolaryngological practice.

Introduction

Voice health is intricately linked to the structural and biochemical integrity of the laryngeal extracellular matrix. The vocal folds ability to vibrate and produce sound is dependent on the precise composition and organization of ECM proteins, glycosaminoglycans, and signaling molecules. Disruption of ECM homeostasis is a hallmark of various laryngeal diseases, including benign vocal fold lesions, scarring, and malignancies. Identification and quantification of ECM biomarkers can enhance understanding of disease mechanisms and improve clinical outcomes through targeted interventions.

Epidemiology / Disease Burden

Laryngeal disorders constitute a significant proportion of otolaryngological consultations globally, with voice disorders affecting approximately 3–9% of the general population, and up to 30% in professional voice users. ECM abnormalities have been implicated in common conditions such as vocal fold nodules, polyps, Reinke’s edema, and carcinoma, contributing to substantial morbidity, quality-of-life impairment, and healthcare expenditure. The growing recognition of ECM biomarkers underscores the need for comprehensive epidemiological studies to delineate their prevalence and impact in diverse populations.

Pathophysiology

The laryngeal ECM comprises collagens (type I, III, IV), elastin, fibronectin, laminin, hyaluronic acid, decorin, and other proteoglycans. These components confer biomechanical properties essential for phonation, including elasticity, viscosity, and tensile strength. Pathological processes such as inflammation, trauma, and neoplasia disrupt ECM synthesis and degradation, mediated by matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), cytokines, and growth factors. Aberrant expression of ECM biomarkers such as increased MMP-9, altered hyaluronic acid concentration, and reduced decorin has been documented in various laryngeal conditions, correlating with tissue remodeling, scarring, and impaired vibratory function.

Risk Factors

Risk factors for ECM disruption in the larynx include phonotrauma, chronic inflammation (e.g., laryngopharyngeal reflux), smoking, infection, radiation exposure, and genetic predisposition. Professional voice users, such as teachers and singers, are particularly susceptible due to repetitive mechanical stress. Moreover, age-related changes in ECM composition such as decreased hyaluronic acid and elastin predispose elderly individuals to voice disorders. Understanding these risk factors is essential for stratifying patients and tailoring preventive strategies targeting ECM integrity.

Clinical Features

Alterations in laryngeal ECM manifest clinically as hoarseness, breathiness, reduced vocal range, vocal fatigue, and loss of vocal endurance. Physical examination may reveal vocal fold lesions, erythema, edema, or scarring. Stroboscopic assessment often demonstrates impaired mucosal wave, stiffness, or non-vibratory segments, which are indicative of underlying ECM pathology. The clinical phenotype of voice disorders is thus directly influenced by the qualitative and quantitative changes in ECM biomarkers.

Diagnosis

Diagnosis of laryngeal ECM alterations relies on a combination of clinical evaluation, laryngostroboscopy, and, increasingly, molecular analysis. Recent advances enable the detection of ECM biomarkers in tissue biopsies, laryngeal secretions, and even non-invasively via salivary samples. Immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), and quantitative PCR are commonly used to assess levels of MMPs, hyaluronic acid, fibronectin, and related markers. Integration of biomarker profiling with imaging findings augments diagnostic accuracy and facilitates personalized management.

Treatment & Management

Management of laryngeal ECM pathology is multifaceted, encompassing voice therapy, pharmacological interventions (e.g., corticosteroids, anti-fibrotic agents), and surgical procedures such as phonomicrosurgery or injection laryngoplasty. Restoration of ECM homeostasis is a therapeutic goal, with ongoing research exploring the efficacy of agents targeting MMP activity, hyaluronic acid supplementation, and regenerative approaches using stem cells or tissue engineering. Clinical outcomes are increasingly assessed with reference to biomarker modulation, guiding treatment selection and monitoring response.

Recent Advances / Emerging Therapies

Emerging therapies focus on targeted modulation of ECM pathways to prevent or reverse pathological remodeling. Recent studies highlight the potential of recombinant growth factors (e.g., hepatocyte growth factor, basic fibroblast growth factor) and anti-fibrotic drugs (e.g., pirfenidone) in mitigating scarring and promoting ECM regeneration. Advances in biomaterials and scaffold design facilitate delivery of ECM components or cells to the larynx. High-throughput omics technologies, including proteomics and transcriptomics, are expanding biomarker discovery and enabling precision medicine approaches in voice care.

Guideline Recommendations

Current clinical guidelines emphasize the importance of early recognition and comprehensive assessment of voice disorders, incorporating evaluation of potential ECM involvement. While routine ECM biomarker testing is not yet standard practice, consensus statements advocate for research-driven integration of molecular diagnostics in refractory or complex cases. Multidisciplinary management, including speech-language pathology, otolaryngology, and, where appropriate, molecular pathology, is recommended to optimize patient outcomes and advance biomarker-driven care.

Conclusion

Laryngeal extracellular matrix biomarkers represent a rapidly evolving frontier in voice health, offering valuable insights into disease mechanisms, diagnostic strategies, and therapeutic innovation. Continued research and clinical validation are essential to translate these molecular findings into routine practice, ultimately improving the management and prognosis of patients with voice disorders. The integration of ECM biomarkers into personalized medicine paradigms holds promise for advancing the field of laryngology and enhancing patient quality of life.